Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations.
about
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse eventsA Single-Nucleotide Polymorphism in ABCC4 Is Associated with Tenofovir-Related Beta2-Microglobulinuria in Thai Patients with HIV-1 InfectionRisk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral TreatmentTotal protein, albumin and low-molecular-weight protein excretion in HIV-positive patients.Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunctionInfluence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patientsCombination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection.Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adultsHigher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV.Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function.Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study.Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis.Urine liver-type fatty acid-binding protein and kidney injury molecule-1 in HIV-infected patients receiving combined antiretroviral treatment based on tenofovir.Tenofovir-induced Fanconi syndrome and osteomalacia in two HIV-infected patients: role of intracellular tenofovir diphosphate levels and review of the literature.Renal dysfunction in the setting of HIV/AIDS.Renal toxicity associated with antiretroviral therapy.Update on tenofovir toxicity in the kidney.Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding.Antiretroviral drug-related toxicities - clinical spectrum, prevention, and management.Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention.Less-drug regimen including atazanavir in maintenance treatment of HIV infection: how, who, when, why?Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women.Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients.Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study.Diagnostic challenges of kidney diseases in HIV-infected patients.Kidney Disease in HIV: Moving beyond HIV-Associated Nephropathy.Evaluating the association of single-nucleotide polymorphisms with tenofovir exposure in a diverse prospective cohort of women living with HIV.Efficacy and safety of "unboosting" atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF.Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines.Brief Report: Cumulative Tenofovir Disoproxil Fumarate Exposure is Associated With Biomarkers of Tubular Injury and Fibrosis in HIV-Infected Men.Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.Tenofovir-Associated Nephrotoxicity in Children with Perinatally-Acquired HIV Infection: A Single-Centre Cohort Study.ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen.Tenofovir nephrotoxicity: 2011 update.Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate.Tenofovir plasma concentrations in post-menopausal versus pre-menopausal HIV-infected women.Depletion of the cellular antioxidant system contributes to tenofovir disoproxil fumarate - induced mitochondrial damage and increased oxido-nitrosative stress in the kidney.The frequency of adjusted renal dosing of tenofovir DF and its effects on patient outcomes.
P2860
Q26995852-008FF10B-8097-458B-A92C-D6FFD77A24C0Q28535587-EA50A46D-7BBC-461C-8F4C-EC04A4EEC744Q28552839-DD789995-C67D-486F-AD72-15A933AC88ECQ28554081-9E079230-2C07-47D8-80A1-DCCEC3D8F3AFQ34375843-D11D933F-E1E2-4277-9837-5515665A348FQ35016654-BF621AE0-8D83-46C2-9F17-604756382E7DQ35607723-160D8769-287B-4C22-BCAA-7C4ECD2EB3E2Q36097686-188B5317-2920-45CD-8C3F-ADF459B1ACB9Q36650454-4C9C16B8-FB29-4B8B-B2BE-2C4F95799D72Q36663586-B7DD04AE-08FF-44CA-8049-1BEDDDA41246Q36757558-99708E86-2A15-4CBE-B3F0-A2DEF91923B2Q37377643-2A4ACB45-3B63-4FDF-BC96-ACDFE78D33FEQ37665912-362A3A45-55AA-49B5-AC8E-229595143819Q37686155-4AAD9795-A59A-4E36-9BCA-C919ECBCBE09Q37874616-A32CB4D6-F3D1-4DED-B153-14A8E9384DD3Q38019428-EEA11115-4DC5-4DE6-9110-A0CE5C044B87Q38031028-70409B19-AB63-4B76-94F1-E0EECA0CF345Q38033446-A440948C-C102-44E7-85EE-E874B8277438Q38051400-9C59D071-778A-4F1A-8D11-57230E67377DQ38111430-830EFCE7-13E0-445E-8A21-BDEFCF8BD062Q38222708-B8573245-B7F2-4F7F-B236-4DF9CE925252Q38818789-9DFDA6B2-5C45-4B18-8227-EDA7B564C4B3Q38836878-1D8B8F93-60C2-4CB0-B21D-4F84DF37AC0EQ38855217-9F819B97-9876-4E33-BBF0-CE5E66DE24FDQ38954109-3D5F6A1E-85FA-4B32-9487-B64DF091C14CQ39033125-87A4E642-198B-4DBC-92B2-C27331B3B596Q40051440-DD95809E-C84E-4B81-9FC5-8D92D2B9BAC8Q40103229-195DE254-9D3C-46E6-8E13-E5AFC31C5489Q40219167-11E95FFD-9E98-44C6-B9AF-E08A2FBE59F0Q40379981-9E875F2E-D90F-4DDC-A1F2-804C9AEEBC78Q40462001-05B5D702-69F1-47B7-A0CC-642931AEC5FDQ40710519-21EEB59C-01FB-4626-8A0D-001A16CE718EQ41204065-96B05F39-3134-404F-8996-39CDF0BAECAAQ41344883-AFFEEE77-8BDC-46E6-BF9E-EE7FF606549FQ42216997-5FF57E40-3A84-4DDE-87CE-DC305C33D451Q42254390-EB36F10D-C492-484A-A20E-FE400FE4D874Q42279462-B1EB24F2-42D8-4F85-B9FF-7F42697EE085Q42279687-A80B2BBA-6A7B-421F-AF2D-36F071AC679FQ42588985-9780BFD0-FFC7-4AA5-826D-489CF656926EQ43798415-56885BF0-D85B-4174-9E33-47E30F3803E4
P2860
Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Impairment in kidney tubular f ...... nofovir plasma concentrations.
@en
Impairment in kidney tubular f ...... nofovir plasma concentrations.
@nl
type
label
Impairment in kidney tubular f ...... nofovir plasma concentrations.
@en
Impairment in kidney tubular f ...... nofovir plasma concentrations.
@nl
prefLabel
Impairment in kidney tubular f ...... nofovir plasma concentrations.
@en
Impairment in kidney tubular f ...... nofovir plasma concentrations.
@nl
P2093
P50
P1433
P1476
Impairment in kidney tubular f ...... enofovir plasma concentrations
@en
P2093
Carmen Solera
Eugenia Vispo
Giovanni Di Perri
Marta Albalate
Pablo Barreiro
Pablo Labarga
Sonia Rodríguez-Nóvoa
Stefano Bonora
P304
P356
10.1097/QAD.0B013E32833202E2
P407
P577
2010-04-01T00:00:00Z